This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

AML

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder characterised by the arrest of differentiation of the progenitor cells (“blasts”) coupled with an accumulation of immature progenitors in the bone marrow, resulting in hematopoietic failure (1):

  • AML is generally a disease of older adults - median age at diagnosis between 65 and 70 year of age (2)
  • in the UK, approximately 66% of cases are diagnosed in people aged 65 years or over (2)
  • in the UK, 56% of AML cases are in males and 44% are in females (2)
  • the overall cure rate for patients between 18 and 60 years of age with AML is 35% to 40% (3)
  • the overall outlook for older patients is poorer than that of younger patients: 5-year relative survival from the time of diagnosis is 38.9% for patients aged 50 to 64 years, and 11.2% for patients aged >65 years. (4,5)
  • AML in older individuals is a more recalcitrant disease
    • the disease tends to be less proliferative with average bone marrow blast counts of 20% in those older than 60 and 40% in those younger than 60. When compared with those younger than 56, those older than 56 are less likely to have favourable cytogenetics (16% vs. 5%) and more likely to have unfavourable cytogenetics (33% vs. 50%) (6)

References:

  1. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011 Mar;152(5):524-42
  2. Cancer Research UK. Acute myeloid leukaemia (AML) incidence statistics. Jul 2024 [internet publication].
  3. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52.
  4. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER*Explorer [internet publication].
  5. Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015 Jan 29;125(5):767-74.
  6. Blood Rev. 2008 Nov;22(6):311-20

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.